Dissociation of Phagocyte Recognition of Cells Undergoing Apoptosis from Other Features of the Apoptotic Program*

Jianguo ZhuangDagger , Yi Ren§, Roger T. SnowdenDagger , Huijun ZhuDagger , Vladimir GogvadzeDagger , John S. Savill§, and Gerald M. CohenDagger parallel

From the Dagger  Medical Research Council Toxicology Unit, Centre for Mechanisms of Human Toxicity, University of Leicester, Hodgkin Building, Lancaster Road, Leicester LEI 9HN and the § Division of Renal and Inflammatory Disease, Department of Medicine, University Hospital, Nottingham NG7 2UH, United Kingdom

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Apoptosis is a programmed form of cell death characterized by biochemical and morphological changes affecting the nucleus, cytoplasm, and plasma membrane. These changes in various cellular compartments are widely regarded as mechanistically linked events in a single "program" in which activation of caspases and proteolysis of intracellular substrates represent a final common pathway leading to cell death. To date there has been very limited exploration of the linkage of this program to the plasma membrane changes, which bring about swift recognition, uptake, and safe degradation of apoptotic cells by phagocytes. Using the mitochondrial inhibitors antimycin A and oligomycin in human monocytic THP.1 cells triggered into apoptosis, we report the uncoupling of plasma membrane changes from other features of apoptosis. These inhibitors blocked increased plasma membrane permeability, externalization of phosphatidylserine, and recognition by two classes of phagocytes but not activation of caspase-3, cleavage of poly(ADP-ribose) polymerase and DNA fragmentation. Externalization of phosphatidylserine in apoptotic human leukemic U937 cells was also dissociated from caspase activation. Thus changes governing safe clearance of apoptotic cells may be regulated by an independent pathway to those bringing about caspase activation. This finding could have important consequences for attempts to manipulate cell death for therapeutic gain in vivo.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Apoptosis is a fundamentally important and programmed form of cell death with wide-ranging significance in health and disease (1, 2). Apoptotic cell death occurs in two phases, an initial commitment phase followed by an execution phase, which is characterized by a series of stereotypic changes including cell shrinkage, plasma membrane alterations, and condensation and fragmentation of chromatin (3). Internucleosomal cleavage of DNA, demonstrated as a DNA ladder by agarose gel electrophoresis, was originally considered as a biochemical hallmark of apoptosis (4), although it is now considered as a late event in apoptosis, which may be dissociated from early more critical changes (5). These DNA ladders are derived from large fragments of DNA of 30-50 and 200-300 kilobase pairs in length (6). A family of at least 10 interleukin-1beta -converting enzymes (now known as caspases) (7) appear to be responsible for most of the biochemical changes associated with the execution phase of apoptosis (reviewed in Refs. 8-10). Caspases are cysteine proteases that have an absolute specificity for an aspartic acid in the P1 position of the substrate and cleave important cellular substrates including lamins, poly(ADP-ribose) polymerase (PARP)1 and DNA-dependent protein kinase (3, 8-10). Cleavage of intact PARP (116 kDa) to its 85-kDa signature fragment is observed in many different types of cells undergoing apoptosis and has also been proposed as a biochemical marker of apoptosis (11). Many if not all caspases are capable of cleaving PARP in vitro, but in intact cells it is likely that caspase-3 (CPP32) and caspase-7 (Mch3) are primarily responsible for the cleavage (8, 10, 12).

In vivo intact cells dying by apoptosis are usually swiftly recognized and safely cleared by phagocytes. This protects surrounding tissues from exposure to injurious contents leaking from dying cells, which is inevitable in accidental cell death by necrosis (1, 13). Currently, there is only limited understanding of the molecular mechanisms that render apoptotic cells recognizable to phagocytes. However, exposure of phosphatidylserine (PS), an anionic phospholipid normally confined to the inner leaflet of the membrane bilayer, serves as a recognition signal for yet to be characterized PS receptors on certain phagocyte populations (14-16). The mechanisms mediating PS exposure are complex but seem to involve activation of caspases (17, 18). Another mechanism by which phagocytes recognize cells undergoing apoptosis involves the phagocyte adhesion receptor CD36 co-operating with the alpha vbeta 3 vitronectin receptor integrin to bind thrombospondin (TSP), which acts as a molecular bridge between the apoptotic cell and the macrophage (19).

We have studied the induction of apoptosis in two human tumor cell lines, THP.1 and U937. Using the mitochondrial inhibitors antimycin A and oligomycin, we now demonstrate for the first time that in THP.1 cells induction of the apoptotic phenotype, characterized by DNA fragmentation and the activation of caspases with ensuing cleavage of PARP, can be dissociated from cell surface changes that result in the phagocytic recognition of apoptotic cells by both the PS and CD36/alpha vbeta 3/TSP mechanisms. Similar dissociation of externalization of phosphatidylserine from activation of caspases was also observed in U937 cells.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Cell Culture and Treatments-- Media and serum were purchased from Life Technologies, Inc. (Paisley, UK). All chemicals were obtained from Sigma Chemical Company (Dorset, UK) except for N-tosyl-L-phenylalanyl chloromethyl ketone (TPCK, Boehringer-Mannheim UK, Lewes, UK) and benzyloxycarbonyl-valinyl-alanyl-aspartyl (OMe) fluoromethyl ketone (Z-VAD.FMK, Enzyme Systems Inc., Dublin, CA). Both human monocytic THP.1 cells and human leukemic U937 cells were maintained in suspension culture as described (20, 2l). Apoptosis was induced in THP.1 cells by incubating cells for 4 h with either etoposide or TPCK, whereas U937 cells were incubated for either 3 h with tumor necrosis factor-alpha (TNF-alpha ) in combination with cycloheximide or 5 h with etoposide. To assess the effects of the inhibitors on apoptosis, antimycin A, oligomycin (65% oligomycin A), and ZVAD.FMK were added 5 min before the cells were treated with apoptotic stimuli in all experiments except for apoptosis induced by TNF-alpha in U937 cells, which were pre-incubated with Z-VAD.FMK for 30 min before exposure to TNF-alpha .

Flow Cytometric Analysis of Apoptosis-- Apoptosis in THP.1 and U937 cells (0.5 × 106 cells) was assessed with Hoechst 33342 and propidium iodide (20, 21). Cells with a high blue fluorescence (Hoechst 33342), because of an increase in cell membrane permeability (22), exhibit an apoptotic morphology together with internucleosomal cleavage of DNA (20, 21). PS exposure in apoptotic cells was detected by incubating cells with fluorescein isothiocyanate-labeled Annexin V (Bender MedSystems, Vienna, Austria) as described (15, 23). Mitochondrial membrane potential (Delta Psi m) was measured following incubation of the cells for 25 min at 37 °C with the fluorochrome 3,3'-dihexyloxacarbocyanine iodide (50 nM) (Molecular Probes Inc., Eugene, OR), which is retained in mitochondria with a normal membrane potential (24).

Western Blot Analysis-- THP.1 and U937 cells (0.5 × 106) were prepared for SDS-polyacrylamide gel electrophoresis as described previously (25). Intact PARP (116 kDa) and its apoptotic 85-kDa signature fragment were detected with a rabbit polyclonal (318) or a mouse monoclonal antibody (C2-10) (from Dr. G. Poirier, Laval University, Quebec, Canada). Procaspase-3 and its catalytically active large subunit were detected with a rabbit polyclonal antibody raised against the p17 subunit of caspase-3 (from Dr. D. Nicholson, Merck Frosst, Quebec, Canada) as described (25).

Internucleosomal Cleavage of DNA-- Agarose gel electrophoresis was used to detect DNA laddering in whole cells (2 × 106) as described previously (5).

Phagocytosis Assay-- Isolation and culture of mouse macrophages were essentially as described previously (26) except for minor modifications as follows. Inflammatory macrophages were elicited into the peritoneal cavity of 8-16-week-old Balb/c mice with 2% Brewer's thioglycollate. Peritoneal exudate cells were harvested 4 days later by peritoneal lavage with balanced salt solution, plated in 96-well plates at 0.1 × 106 cells/well, and cultured overnight in complete medium (Dulbecco's modified Eagle's medium containing 5% fetal calf serum, 50 mM 2-mercaptoethanol, 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin) before use in the phagocytosis assay. Bone marrow was harvested from Balb/c mice and plated at 0.1 × 106 cells/well in 96-well plates in Dulbecco's modified Eagle's medium containing 10% conditioned medium from L929 cells as a source of macrophage colony-stimulating factor. Bone marrow macrophages were used in the phagocytosis assay after being cultured for 5-7 days. For the phagocytosis assays, macrophage monolayers were washed, and THP.1 cells (0.5 × 106) in RPMI 1640 containing 5% fetal calf serum were added to each well. The plates were incubated for 1 h and then washed in ice-cold saline after treatment with trypsin to remove adherent macrophages. After cytospinning the macrophages onto microscope slides, cells were fixed with 2% glutaraldehyde and stained with Giemsa dye. Phagocytosis was evaluated by counting 500 macrophages/slide of four replicate slides in each experiment. Results were expressed as the percentages of macrophages that had phagocytosed THP.1 cells.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Antimycin A and Oligomycin Inhibit Apoptosis Assessed by PS Exposure and Hoechst Staining but Not by Decreased Mitochondrial Membrane Potential (Delta Psi )-- Treatment of THP.1 cells with etoposide, a DNA topoisomerase II inhibitor, or TPCK, a chymotrypsin-like serine protease inhibitor, induces apoptosis, assessed by an increase in Hoechst 33342 fluorescence (20, 25, 27). Increase in Hoechst fluoresence results from an increased cell permeability of apoptotic cells compared with normal cells (22). In this study we have also assessed apoptosis using two other flow cytometric methods, i.e. externalization of PS and the percentage of cells with decreased Delta Psi m. Externalization of PS is considered to be a general feature of apoptosis induced by many different stimuli and is measured by binding of annexin V, a PS-binding protein (15, 23). A reduction in Delta Psi m has also been reported to be an early event in the induction of apoptosis in many different systems (28, 29). Incubation of THP.1 cells with etoposide (25 µM) or TPCK (75 µM) resulted in a time-dependent induction of apoptosis, as assessed by both PS exposure and decreased Delta Psi m (Table I). Although a decreased Delta Psi m has been proposed to regulate the externalization of PS (29), in our studies both of these changes demonstrated a similar time dependence irrespective of the apoptotic stimulus (Table I). Thus induction of apoptosis in THP.1 cells is accompanied by an increased Hoechst 33342 fluorescence, externalization of PS, and a decreased Delta Psi m.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Time-dependent induction of apoptosis by etoposide and TPCK in THP.1 cells
THP.1 cells were incubated for up to 4 h with either etoposide (25 µM) or TPCK (75 µM). The percentage of apoptotic cells was then determined by an increase in PS externalization or a decrease in Delta Psi m. The data represent the means (± S.E.) of at least three experiments.

To investigate the possible relationship between reduction in mitochondrial Delta Psi and other features of apoptosis such as externalization of PS, we used antimycin A and oligomycin, inhibitors of the mitochondrial respiratory chain and ATP synthase, respectively (30). Both antimycin A and oligomycin caused a concentration-dependent inhibition of apoptosis induced by either etoposide or TPCK as assessed either by PS exposure or Hoechst 33342 staining, whereas they had little effect on the decreased Delta Psi m (Fig. 1). Neither antimycin A nor oligomycin alone induced apoptosis assessed by PS exposure, Hoechst 33342 staining, or DNA fragmentation (data not shown). Thus these experiments dissociated those features of the apoptotic phenotype assessed by PS exposure and Hoechst 33342 staining from those measured by the changes in Delta Psi m.


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 1.   Antimycin A and oligomycin cause a concentration-dependent inhibition of externalization of PS and increase in Hoechst 33342 fluoresence but not of the reduction in Delta Psi m. THP.1 cells were incubated for 4 h with either etoposide (25 µM) (A) or TPCK (75 µM) (B) either alone or in the presence of the indicated concentrations of antimycin A (1-30 µM) or oligomycin (0.1-5 µg/ml) or in the presence of Z-VAD.FMK (50 µM). The percentage of apoptotic cells was then measured flow cytometrically using an increase in externalization of PS (open bars), an increase in Hoechst 33342 fluoresence (filled bars), or a decrease in Delta Psi m (diagonally hatched bars). The data represent the means (± S.E.) of at least three experiments.

Z-VAD.FMK (50 µM), a cell membrane-permeable inhibitor of caspases, inhibited apoptosis induced by both etoposide and TPCK, as assessed by all three methods (Fig. 1), supporting a role for caspases in the execution phase of apoptosis in THP.1 cells in agreement with our previous observations (20, 25, 27). These results demonstrated that in this model of apoptosis the activation of caspases occurred upstream of PS exposure, increased Hoechst 33342 staining, and a decrease in Delta Psi m.

Dissociation of PS Externalization from Caspase-3 Activation and PARP Cleavage-- During the execution phase of apoptosis, caspases are activated and cleave cellular substrates, such as PARP (3, 8-12). Therefore we wished to examine whether the mitochondrial inhibitors differentially affected the activation of caspases and the cleavage of PARP. Using Western blot analysis, control cells contained almost entirely intact PARP (116 kDa) (Fig. 2A, lane 1). Induction of apoptosis by either TPCK or etoposide was accompanied by the cleavage of PARP to its 85-kDa signature fragment (Fig. 2A, lanes 2 and 6), which was completely blocked by Z-VAD.FMK (50 µM) (Fig. 2A, lanes 5 and 9), further supporting the involvement of caspases in the execution phase of apoptosis in THP.1 cells. Neither oligomycin nor antimycin A blocked proteolysis of PARP to its 85-kDa fragment following incubation with either TPCK (Fig. 2A, lanes 3 and 4) or etoposide (Fig. 2A, lanes 7 and 8). The cleavage of PARP to its 85-kDa signature fragment, which occurs at a DEVDdown-arrow G sequence separating the amino-terminal DNA binding domain and carboxyl-terminal catalytic domain of the enzyme (31), suggested the activation of caspase-3 (CPP32) and/or caspase-7 (Mch3). We therefore examined the activation of caspase-3 using an antibody raised against its p17 large subunit. Caspase-3 is usually present in intact cells as an inactive p32 proform (25, 32). On induction of apoptosis it is initially processed at Asp175 between the large and small subunits yielding a p20 subunit, which is further processed at Asp9 and Asp28 to yield p19 and p17 large subunits, respectively (12, 33). Control THP.1 cells showed the presence of the intact proform of caspase-3 (Fig. 2B, lane 1). Induction of apoptosis with either TPCK or etoposide was accompanied by loss of the proform of caspase-3 together with formation of the catalytically active large subunit of caspase-3 (Fig. 2B, LS, lanes 2 and 6). Cleavage of caspase-3 was more extensive in response to TPCK compared with etoposide commensurate with the greater induction of apoptosis induced by this stimulus. Z-VAD.FMK, which blocked the induction of apoptosis induced by these stimuli (Fig. 1), almost totally blocked the formation of the large subunit of caspase-3 in cells treated with either TPCK (Fig. 2B, lane 5) or etoposide (Fig. 2B, lane 9), although a small amount of a slightly larger immunoreactive fragment (~p20) was also observed (Fig. 2B, lane 9), which was catalytically inactive because of the lack of the cleavage of PARP (Fig. 2A, lane 9). In contrast, neither oligomycin nor antimycin A inhibited the activation of caspase-3 after treatment with either TPCK (Fig. 2B, lane 3 and 4) or etoposide (Fig. 2B, lane 7 and 8). Thus oligomycin and antimycin A inhibited the externalization of PS and the increase in cell membrane permeability assessed by Hoechst 33342 staining (Fig. 1A) but did not inhibit the activation of caspase-3 and cleavage of PARP (Fig. 2).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 2.   Z-VAD.FMK but not antimycin A or oligomycin inhibits PARP cleavage and caspase-3 activation in THP.1 cells. THP.1 cells were incubated for 4 h with either TPCK (75 µM) or etoposide (25 µM) in the presence or absence of oligomycin (Oligo, 5 µg/ml), antimycin A (Ant, 30 µM), or Z-VAD.FMK (Z-VAD, 50 µM). A, to detect the 85-kDa fragment of PARP, cellular proteins were resolved on an SDS-7% polyacrylamide gel, transferred onto nitrocellulose membrane, and probed with rabbit antiserum (318). B, to detect caspase-3 activation, cellular proteins were resolved on an SDS-15% polyacrylamide gel. After transferring, the proteins were probed with rabbit polyclonal antibodies raised against the large subunit (LS) of caspase-3. Results are representative of three experiments.

Dissociation of Externalization of PS from DNA Fragmentation-- To extend these studies, we investigated whether the treatment with antimycin A or oligomycin had interfered with the DNA fragmentation, which occurs late in apoptosis. Etoposide alone induced internucleosomal cleavage of DNA compared with control cells (Fig. 3, compare lanes 1 and 2). Z-VAD.FMK (50 µM) but not antimycin A or oligomycin inhibited etoposide-induced internucleosomal cleavage (Fig. 3, lanes 3-5). TPCK alone induced fragmentation of DNA to large fragments of 30-50, 200-300, and 600-700 kilobase pairs in length in the absence of internucleosomal cleavage (27). Z-VAD.FMK but not antimycin A or oligomycin inhibited the formation of these large DNA fragments (data not shown). Thus externalization of PS during apoptosis can also be dissociated from DNA fragmentation.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 3.   Neither antimycin A nor oligomycin inhibits internucleosomal cleavage of DNA in THP.1 cells. THP.1 cells were incubated with etoposide (25 µM) in the presence or absence of oligomycin (Oligo, 5 µg/ml), antimycin A (Ant, 30 µM), and Z-VAD.FMK (Z-VAD, 50 µM) for 4 h. 2 × 106 cells were loaded per lane and subjected to conventional agarose gel electrophoresis to detect internucleosomal cleavage of DNA. Results are representative of three experiments.

Cell Surface Changes Resulting in Phagocytic Recognition Can Be Dissociated from Other Features of the Apoptotic Phenotype-- One of the key features of the apoptotic process is the rapid recognition and subsequent phagocytosis of apoptotic cells (1, 13). Because both antimycin A and oligomycin inhibited externalization of PS but not other features of the apoptotic phenotype, we wished to assess whether they also interfered with phagocytic recognition of apoptotic THP.1 cells. Peritoneal and bone marrow macrophages phagocytose apoptotic cells utilizing receptors for PS or thrombospondin (i.e. alpha vbeta 3 and CD36), respectively (13, 14, 19, 26). Exposure of THP.1 cells to the two pro-apoptotic stimuli, etoposide and TPCK, resulted in an increase in the percentage of cells phagocytosed by both peritoneal macrophages and bone marrow-derived macrophages (Table II). Z-VAD.FMK, antimycin A, and oligomycin all inhibited the etoposide- and TPCK-induced increases in recognition and phagocytosis by both peritoneal and bone marrow-derived macrophages (Table II). Thus cells displaying many features of apoptosis including DNA fragmentation, processing of caspase-3, and PARP cleavage do not display characteristic cell surface changes, which result in phagocytic recognition and engulfment.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Inhibition of phagocytosis of apoptotic THP.1 cells by oligomycin and antimycin A
Induction of apoptosis in THP.1 cells was essentially as described in the legend to Table I. Phagocytosis was evaluated by counting 500 macrophages/slide of four replicate slides in each experiment (see "Experimental Procedures"). Peritoneal and bone marrow macrophages phagocytose apoptotic cells utilizing receptors for PS and thrombospondin, respectively. Results were expressed as percentages of macrophages that had phagocytosed THP.1 cells. The data represent the means (± S.E.) of three experiments.

Dissociation of Cell Membrane Changes from Caspase Activation during Induction of Apoptosis in U937 Cells-- To determine whether the phenomenon of dissociation of externalization of PS from other features of the apoptotic phenotype was cell type-specific, we extended the study to human leukemic U937 cells. These cells were treated with two commonly used apoptotic stimuli, etoposide (25 µM) or TNF-alpha (10 ng/ml) in the presence of cycloheximide (0.9 µM) (17). Apoptosis was induced by both these stimuli, as assessed by externalization of PS, increase in Hoechst 33342 fluoresence, and increase in cells with a decreased Delta Psi m (Fig. 4A). Both oligomycin (5 µg/ml) and antimycin A (30 µM) largely blocked the apoptotic changes induced by either TNF-alpha or etoposide as assessed either by PS exposure or Hoechst 33342 staining but had little effect on the decreased Delta Psi m (Fig. 4A). Control U937 cells contained almost entirely intact PARP (116 kDa) (Fig. 4B, lane 1). Induction of apoptosis by either TNF-alpha or etoposide was accompanied by activation of caspases as assessed by the cleavage of PARP to its 85-kDa signature fragment (Fig. 4B, lanes 2 and 6). This cleavage was completely blocked by Z-VAD.FMK (Fig. 4B, lanes 5 and 9), further supporting the activation of caspases during apoptosis. Apoptosis, assessed by PS exposure, Hoechst 33342 staining, or PARP cleavage was not induced by either antimycin A or oligomycin alone (data not shown). Neither antimycin A nor oligomycin blocked proteolysis of PARP to its 85-kDa fragment following incubation with either TNF-alpha (Fig. 4B, lanes 3 and 4) or etoposide (Fig. 4B, lanes 7 and 8). Thus, these results in U937 cells dissociated those features of the apoptotic phenotype assessed by PS exposure and Hoechst 33342 staining from those measured by the changes in Delta Psi m and caspase activation.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   Dissociation of PS externalization from caspase activation in apoptotic U937 cells. Apoptosis was induced in U937 cells following incubation for either 3 h with TNF-alpha (10 ng/ml) in the presence of cycloheximide (0.9 µM) (lanes 2-5) or 5 h with etoposide (25 µM) (lanes 6-9). U937 cells were incubated either alone (lane 1) or with the apoptotic stimuli in the presence of antimycin A (30 µM) (lanes 3 and 7) or oligomycin (5 µg/ml) (lanes 4 and 8). Cells were also incubated with the apoptotic stimuli in the presence of the caspase inhibitor Z-VAD.FMK, the concentration of which was either 2 or 20 µM in the case of TNF-alpha or etoposide, respectively (lanes 5 and 9). A, the percentage of apoptotic cells was then measured flow cytometrically using either increase in externalization of PS (open bars), increase in Hoechst 33342 fluoresence (filled bars), or decrease in Delta Psi m (diagonally hatched bars). The data represent the mean (± S.E.) of at least three experiments except for Delta Psi m, which represents the mean of two determinations. B, cellular proteins were resolved on SDS-10% polyacrylamide gels, transferred onto nitrocellulose membrane, and probed with a mouse monoclonal antibody (C2-10) to detect both intact PARP (116 kDa) and its cleaved 85-kDa fragment.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In this paper we present data demonstrating the dissociation of cell membrane changes leading to phagocyte recognition of cells undergoing apoptosis from other features of this programmed form of cell death. The mitochondrial inhibitors, antimycin A and oligomycin, not only inhibited surface changes of apoptosis, such as PS exposure and recognition by PS-dependent elicited murine peritoneal macrophages but also inhibited surface changes recognized by murine bone marrow-derived macrophages, which use the alpha vbeta 3/thrombospondin recognition mechanism (Table II). However, antimycin A and oligomycin did not inhibit caspase-3 activation, cleavage of PARP, DNA degradation, and reduction in Delta Psi m (Figs. 1-4). These data imply that the surface changes of apoptosis relate to an independent pathway of events, which may be differentially regulated from the activation of "effector" caspases, which are believed to trigger the nuclear and some of the cytoplasmic changes of apoptosis.

It has become a widely held view that PS exposure and associated changes, such as increased plasma membrane permeability to Hoechst dye, represent "early" features of a single, coordinately regulated common pathway leading to cell death, whereas DNA degradation is a "late" feature. However, temporal dissociation of membrane changes including PS exposure from other features of apoptosis could also imply that mechanisms regulating the ability of dying cells to be recognized by phagocytes are part of a parallel process, which is potentially independent from other features of the program. This interpretation of the data is strongly supported by the effects of antimycin A and oligomycin reported here. Future studies will need to characterize the pathway by which dying cells display "eat me" signals. The effects of Z-VAD.FMK reported here support previous data implicating caspase activation in externalization of PS (17, 18), although effector caspases such as caspase-3 appear not to be involved.

The blockade of this putative "recognition pathway" by antimycin A and oligomycin also provides important clues for its further dissection. A critical role for the mitochondrial release of proteins, such as apoptosis-inducing factor (AIF) and cytochrome c, has been proposed in initiating the apoptotic program including DNA fragmentation and activation of caspase-3 (34, 35). Bcl-2 may prevent apoptosis in part by blocking the mitochondrial release of both AIF and/or cytochrome c (34, 36, 37). Although antimycin A and oligomycin may affect targets other than their known mitochondrial ones, our results suggest that their interference of mitochondrial function prevents the mitochondrial release of some factor(s), other than cytochrome c or AIF, that directly or indirectly results in exposure of PS.

Lastly, our findings could have very important consequences for attempts to manipulate apoptosis for therapeutic gain. In disorders characterized by unscheduled cell loss by apoptosis, such as neurodegenerative disease, potential therapies will not only need to block intracellular pathways leading to engagement of effector enzymes but will also need to interfere with those governing recognition, lest potentially rescued cells are undesirably removed by phagocytes. Conversely, there may be potential for selective triggering of the surface changes of apoptosis in "undesirable" cells (such as cancer cells) so that these are removed by innate mechanisms.

    ACKNOWLEDGEMENTS

We thank Dr. G. G. Poirier for PARP antibody and Dr. D. W. Nicholson for the caspase-3 antibody.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by the European Science Foundation Program in Toxicology. Present address: Inst. of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino 142292 Russia.

parallel To whom correspondence should be addressed: MRC Toxicology Unit, Centre for Mechanisms of Human Toxicity, University of Leicester, Hodgkin Bldg., P.O. Box 138, Lancaster Road, Leicester LEI 9HN, UK. Tel.: 44-116-252-5589; Fax: 44-116-252-5616; E-mail: gmc2{at}le.ac.uk.

1 The abbreviations used are: PARP, poly(ADP-ribose) polymerase; TPCK, N-tosyl-L-phenylalanyl chloromethyl ketone; Z-VAD.FMK, benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethyl ketone; PS, phosphatidylserine; TSP, thrombospondin; TNF-alpha , tumor necrosis factor-alpha ; AIF, apoptosis-inducing factor.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Arends, M. J., and Wyllie, A. H. (1991) Int. Rev. Exp. Pathol. 32, 223-254[Medline] [Order article via Infotrieve]
  2. Thompson, C. B. (1995) Science 267, 1456-1462[Medline] [Order article via Infotrieve]
  3. Earnshaw, W. C. (1995) Curr. Opin. Cell Biol. 7, 337-343[CrossRef][Medline] [Order article via Infotrieve]
  4. Wyllie, A. H. (1980) Nature 284, 555-556[Medline] [Order article via Infotrieve]
  5. Cohen, G. M., Sun, X.-M., Snowden, R. T., Dinsdale, D., and Skilleter, D. N. (1992) Biochem. J. 286, 331-334[Medline] [Order article via Infotrieve]
  6. Brown, D. G., Sun, X.-M., and Cohen, G. M. (1993) J. Biol. Chem. 268, 3037-3039[Abstract/Free Full Text]
  7. Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W., and Yuan, J. (1996) Cell 87, 171[Medline] [Order article via Infotrieve]
  8. Kumar, S., and Lavin, M. F. (1996) Cell Death Differ. 3, 255-267
  9. Henkart, P. A. (1996) Immunity 4, 195-201[Medline] [Order article via Infotrieve]
  10. Cohen, G. M. (1997) Biochem. J. 326, 1-16[Medline] [Order article via Infotrieve]
  11. Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E., and Poirier, G. G. (1993) Cancer Res. 53, 3976-3985[Abstract]
  12. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T.-T., Yu, V. L., and Miller, D. K. (1995) Nature 376, 37-43[CrossRef][Medline] [Order article via Infotrieve]
  13. Savill, J., Fadok, V., Henson, P., and Haslett, C. (1993) Immunol. Today 14, 131-136[CrossRef][Medline] [Order article via Infotrieve]
  14. Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L., and Henson, P. M. (1992) J. Immunol. 148, 2207-2216[Abstract/Free Full Text]
  15. Martin, S. J., Reutelingsperger, C. P. M., McGahon, A. J., Rader, J. A., van Schie, R. C. A. A., LaFace, D. M., and Green, D. R. (1995) J. Exp. Med. 182, 1545-1556[Abstract]
  16. Verhoven, B., Schlegel, R. A., and Williamson, P. (1995) J. Exp. Med. 182, 1597-1601[Abstract]
  17. Vanags, D. M., Pörn-Ares, M. I., Coppola, S., Burgess, D. H., and Orrenius, S. (1996) J. Biol. Chem. 271, 31075-31085[Abstract/Free Full Text]
  18. Martin, S. J., Finucane, D. M., Amarante-Mendes, G. P., O'Brien, G. A., and Green, D. R. (1996) J. Biol. Chem. 271, 28753-28756[Abstract/Free Full Text]
  19. Savill, J., Dransfield, I., Hogg, N., and Haslett, C. (1990) Nature 343, 170-173[CrossRef][Medline] [Order article via Infotrieve]
  20. Zhu, H., Fearnhead, H. O., and Cohen, G. M. (1995) FEBS Lett. 374, 303-308[CrossRef][Medline] [Order article via Infotrieve]
  21. Bicknell, G. R., Snowden, R. T., and Cohen, G. M. (1994) J. Cell Sci. 107, 2483-2489[Abstract/Free Full Text]
  22. Ormerod, M. G., Sun, X.-M., Snowden, R. T., Davies, R., Fearnhead, H., and Cohen, G. M. (1993) Cytometry 14, 595-602[Medline] [Order article via Infotrieve]
  23. Koopman, G., Reutelingsperger, C. P. M., Kuijten, G. A. M., Keehnen, R. M. J., Pals, S. T., and van Oers, M. H. J. (1994) Blood 84, 1415-1420[Abstract/Free Full Text]
  24. Petit, P. X., O'Connor, J. E., Grunwald, D., and Brown, S. C. (1990) Eur. J. Biochem. 194, 389-397[Abstract]
  25. MacFarlane, M., Cain, K., Sun, X.-M., Alnemri, E. S., and Cohen, G. M. (1997) J. Cell Biol. 137, 469-479[Abstract/Free Full Text]
  26. Fadok, V. A., Savill, J. S., Haslett, C., Bratton, D. L., Doherty, D. E., Campbell, P. A., and Henson, P. M. (1992) J. Immunol. 149, 4029-4035[Abstract/Free Full Text]
  27. Zhu, H., Dinsdale, D., Alnemri, E. S., and Cohen, G. M. (1997) Cell Death Differ. 4, 590-599[CrossRef][Medline] [Order article via Infotrieve]
  28. Zamzami, N., Susin, S. A., Marchetti, P., Hirsch, T., Gómez-Monterrey, I., Castedo, M., and Kroemer, G. (1996) J. Exp. Med. 183, 1533-1544[Abstract]
  29. Castedo, M., Hirsch, T., Susin, S. A., Zamzami, N., Marchetti, P., Macho, A., and Kroemer, G. (1996) J. Immunol. 157, 512-521[Abstract]
  30. Nicholls, D. G, and Ferguson, S. J. (1992) Bioenergetics 2, pp. 132-133 and 191-192, Academic Press, London
  31. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. (1994) Nature 371, 346-347[CrossRef][Medline] [Order article via Infotrieve]
  32. Schlegel, J., Peters, I., Orrenius, S., Miller, D. K., Thornberry, N. A., Yamin, T.-T., and Nicholson, D. W. (1996) J. Biol. Chem. 271, 1841-1844[Abstract/Free Full Text]
  33. Fernandes-Alnemri, T., Armstrong, R. C., Krebs, J., Srinivasula, S. M., Wang, L., Bullrich, F., Fritz, L. C., Trapani, J. A., Tomaselli, K. J., Litwack, G., and Alnemri, E. S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7464-7469[Abstract/Free Full Text]
  34. Susin, S. A., Zamzami, N., Castedo, M., Hirsch, T., Marchetti, P., Macho, A., Daugas, E., Geuskens, M., and Kroemer, G. (1996) J. Exp. Med. 184, 1331-1341[Abstract]
  35. Liu, X., Kim, C. N., Yang, J., Jemmerson, R., and Wang, X. (1996) Cell 86, 147-157[Medline] [Order article via Infotrieve]
  36. Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T.-I., Jones, D. P., and Wang, X. (1997) Science 275, 1129-1132[Abstract/Free Full Text]
  37. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. (1997) Science 275, 1132-1136[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.